SCHEMBL6670041

SCHEMBL6670041

CCn1c(C(=O)OC)c(N)c(C#N)c1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
TSHR P16473 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 3/20 0.42
GAA P10253 1/20 0.42
PLA2G1B P04054 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 7/20 0.40
ALOX15 P16050 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK1 P28482 1/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27616300 0.87 ALDH1A1 (0.52) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL3937151 0.85 ALDH1A1 (0.50) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL3945483 0.84 ALDH1A1 (0.58) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL3945351 0.80 ALDH1A1 (0.45) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL3936552 0.80 ALDH1A1 (0.45) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL3938356 0.79 ALDH1A1 (0.44) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL6672131 0.77 ALDH1A1 (0.46) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL3944634 0.77 TSHR (0.72) ALDH1A1TSHRMEN1KMT2AGAA
SCHEMBL7125525 0.74 ALDH1A1 (0.59) ALDH1A1TSHRMEN1KMT2AHPGD
SCHEMBL6670606 0.73 ALDH1A1 (0.44) ALDH1A1TSHRMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383771-A1 9-DEAZAGUANINE DERIVATIVES AS INHIBITORS OF GSK-3 Vertex Pharmaceuticals Incorporated (US) 2004-01-28 EP disclosed
US-20030096813-A1 Compositions useful as inhibitors of GSK-3 CAO JINGRONG (US) 2003-05-22 US disclosed
WO-2002085909-A1 9-DEAZAGUANINE DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096813-A1 Compositions useful as inhibitors of GSK-3 GSK3B, GSK3A, GSKIP ALDH1A1 3164/4885TSHR 3679/4885MEN1 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.